Tenax Therapeutics Inc., a specialty pharmaceutical company focused on cardiovascular and pulmonary diseases, is accelerating enrollment in a Phase 2 trial.

The company now expects full enrollment and top-line data in the first half of 2020. The trial evaluates levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.

Tenax’s trial has 12 activated sites and the company plans to add three more over the next few weeks. The study currently has eight patients enrolled out of a targeted 36 patients.

“Based on feedback from our principal investigators we have modified and adapted our protocols for the HELP trial,” Anthony DiTonno, CEO of Tenax Therapeutics, said in a press release Friday. “These modifications, in addition to achieving our targeted number of clinical sites, have resulted in an acceleration in the pace of patient enrollment.”

Tenax Therapeutics shares were trading at $1.24 on Friday afternoon, up six cents.